# Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Study · id `cardio:ct-nct01053936` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01053936](<https://clinicaltrials.gov/study/NCT01053936>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01053936

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT01053936. Randomized; no masking; primary purpose treatment. Start 2010-01-31 (actual); primary completion 2010-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT01053936, source copy `cardio:ctgov-nct01053936-2025-05-29`, retrieved 2026-10-26)
- Started: 2010-01-31 (actual) (ClinicalTrials.gov record NCT01053936, source copy `cardio:ctgov-nct01053936-2025-05-29`, retrieved 2026-10-26)
- Primary completion: 2010-12-31 (actual) (ClinicalTrials.gov record NCT01053936, source copy `cardio:ctgov-nct01053936-2025-05-29`, retrieved 2026-10-26)
- Completion: 2011-02-28 (actual) (ClinicalTrials.gov record NCT01053936, source copy `cardio:ctgov-nct01053936-2025-05-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01053936, source copy `cardio:ctgov-nct01053936-2025-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01053936-2025-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Condition: Renal Insufficiency, Chronic
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Bardoxolone methyl (amorphous dispersion)
- Lead sponsor: Biogen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Biogen (`cardio:org-biogen`)

## Provenance

Content hash: f432c246b7e00d293b85009c0cbba2dcdb03c72da6dc0d8b2d0ea1b1f36cacab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
